Search

Emicizumab

Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. … The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents.

Carmustine

(From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). … It is used in the treatment of brain tumors and various other malignant neoplasms.

Tamoxifen

Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. … [L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole].

Potassium sulfate

Chromium picolinate

Chromium ions are shown to regulate insulin by promoting glucose utilization and increasing the sensitivity of the insulin receptor [A27235].

Bendroflumethiazide

(From Martindale, The Extra Pharmacopoeia, 30th ed, p810) … A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders.

Dihydro-alpha-ergocryptine

Alpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine. These two compounds are differentiated in the position of a methyl group. … To know more about this mixture, please visit [DB01049]

Evening primrose oil

[A33131] Evening primrose oil has been filled for the FDA by Humanetics Corporation on April 2000 to be a new dietary ingredient but its current status is "Inadequate basis for expectation of safety". … [L2845] By Health Canada, evening primrose oil is approved in over-the-counter combination dietary supplements.[L1113] By the EMA, evening primrose oil is approved in herbal preparations.[L2851]

Tirzepatide

[A246265] Tirzepatide was approved by the FDA on May 13, 2022, under the brand name MOUNJARO by the FDA for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor … Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor

Pixantrone

However, it is notable that the EXTEND trial was stopped early, leaving the statistical significance of the results in question. … Pixantrone does not bind iron and promotes the formation of reactive oxygen species to a lesser degree than other anthracyclines.